The history of copyright's flagship drug presents a nuanced case for investors in the medicinal sector. While initially a blockbuster success, creating huge profits, the intellectual property expiration and the subsequent entry of cheaper versions have considerably impacted income. This presents questions about the ongoing viability of analogous me